The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure

被引:54
作者
Strahlman, ER
Vogel, R
Tipping, R
Clineschmidt, CM
Lewis, R
Keates, E
Quigley, H
Zimmerman, T
Abelson, MB
Allen, RC
Brown, RH
Cacioppo, LR
Cyrlin, MN
Gieser, DK
Greenidge, KC
Gross, RL
Karp, DW
Koby, MM
Kass, M
Laibovitz, R
McMahon, CD
Ostrov, CS
Walters, T
Ritch, R
Samples, JR
Schuman, SJ
Serle, J
VelaThomas, MA
Boyle, J
Lippa, E
Reines, S
Strahlman, E
Strohmaier, K
机构
[1] MERCK RES LABS,DEPT STAT,W POINT,PA
[2] UNIV LOUISVILLE,LOUISVILLE,KY 40292
关键词
D O I
10.1016/S0161-6420(96)30509-5
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To report the results of two studies on the use of dorzolamide as adjunctive therapy to timolol in patients with elevated intraocular pressure (IOP). in the larger study, the additive effect of dorzolamide administered twice daily also was compared with 2% pilocarpine. Methods: Both studies were parallel, randomized, double-masked, placebo-controlled comparisons, In the pilot study, 32 patients received 0.5% timolol twice daily plus either 2% dorzolamide twice daily or placebo twice daily for 8 days. In the Pilocarpine Comparison Study, 261 patients received 0.5% timolol twice daily plus 0.7% dorzolamide twice daily, 2% dorzolamide twice daily, 2% pilocarpine four times daily, or placebo (twice daily or 4 times daily) for 2 weeks, Patients then entered a 6-month extension period and received 0.5% timolol twice daily plus either 0.7% dorzolamide twice daily, 2% dorzolamide twice daily, or 2% pilocarpine four times daily. Results: In the pilot study, after 8 days, additional mean percent reductions in IOP for 2% dorzolamide and placebo were 17% and 3% at morning trough and 19% and 2% at peak, respectively. In the Pilocarpine Comparison Study, after 6 months, additional mean percent reductions in IOP (morning trough) were 9%, 13%, and 10% for 0.7% dorzolamide, 2% dorzolamide, and 2% pilocarpine, respectively, Patients receiving 2% pilocarpine had the highest rate of discontinuation due to a clinical adverse experience, and the use of dorzolamide was not associated with systemic side effects commonly observed with the use of oral carbonic anhydrase inhibitors. Conclusion: Dorzolamide twice daily was effective and well tolerated by the patients in these studies as adjunctive therapy to timolol, The larger study demonstrated that both concentrations of dorzolamide produce similar IOP-lowering effects to 2% pilocarpine.
引用
收藏
页码:1283 / 1293
页数:11
相关论文
共 17 条
[1]   SEPARATE AND COMBINED EFFECTS OF TIMOLOL MALEATE AND ACETAZOLAMIDE IN OPEN-ANGLE GLAUCOMA [J].
BERSON, FG ;
EPSTEIN, DL .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1981, 92 (06) :788-791
[2]  
Berson FG, 1980, PERSPECT OPHTHALMOL, V4, P91
[3]  
CHANDLER PA, 1986, CHANDLER GRANTS GLAU, P141
[4]   CARBONIC-ANHYDRASE INHIBITOR SIDE-EFFECTS - SERUM CHEMICAL-ANALYSIS [J].
EPSTEIN, DL ;
GRANT, WM .
ARCHIVES OF OPHTHALMOLOGY, 1977, 95 (08) :1378-1382
[5]  
HEIJL A, IN PRESS OPHTHALMOLO
[6]  
Kass M A, 1983, Surv Ophthalmol, V28 Suppl, P274, DOI 10.1016/0039-6257(83)90149-2
[7]  
Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
[8]   THE EPIDEMIOLOGY OF OPEN-ANGLE GLAUCOMA - A REVIEW [J].
LESKE, MC .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1983, 118 (02) :166-191
[9]  
LIPPA EA, 1991, OPHTHALMOLOGY, V98, P308
[10]   DOSE-RESPONSE AND DURATION OF ACTION OF DORZOLAMIDE, A TOPICAL CARBONIC-ANHYDRASE INHIBITOR [J].
LIPPA, EA ;
CARLSON, LE ;
EHINGER, B ;
ERIKSSON, LO ;
FINNSTROM, K ;
HOLMIN, C ;
NILSSON, SEG ;
NYMAN, K ;
RAITTA, C ;
RINGVOLD, A ;
TARKKANEN, A ;
VEGGE, T ;
DEASY, D ;
HOLDER, D ;
YTTEBORG, J .
ARCHIVES OF OPHTHALMOLOGY, 1992, 110 (04) :495-499